Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Pimasertib (Primary) ; Voxtalisib (Primary)
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors EMD Serono; Merck KGaA
- 20 Dec 2019 Results (n=65) published in the Gynecologic Oncology.
- 16 Feb 2018 This trial is completed in Spain according to the European Clinical Trials Database record.
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.